Patents by Inventor Alona Zilberberg

Alona Zilberberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • POLYMORPHISM IN THE BCL2 GENE DETERMINES RESPONSE TO CHEMOTHERAPY
    Publication number: 20170152569
    Abstract: Provided are methods useful for determining the expected efficacy of certain chemotherapy treatments and methods of treating cancer based on said determination. In particular, provides are methods and procedures of predicting the efficacy of paclitaxel treatments in cancer patients.
    Type: Application
    Filed: June 18, 2015
    Publication date: June 1, 2017
    Applicant: HIDENSEQ
    Inventors: Sol EFRONI, Alona ZILBERBERG, Rotem BEN-HAMO
  • Cover-slips for an optical microscope and related methods
    Patent number: 9360661
    Abstract: A cover-slip suitable for use in examination by an optical microscope. The cover-slip comprises a planar portion of substantially rigid and transparent material and further comprises a tab contiguous with or adjacent to or attached with the planar portion. The tab is divertable from the plane of the planar portion along a predetermined bending region, thereby allowing holding and displacing the cover-slip e.g. when the cover-slip lies on a flat surface.
    Type: Grant
    Filed: September 23, 2013
    Date of Patent: June 7, 2016
    Inventors: Alona Zilberberg, Amir Zilberberg
  • COVER-SLIPS FOR AN OPTICAL MICROSCOPE AND RELATED METHODS
    Publication number: 20150260977
    Abstract: A cover-slip suitable for use in examination by an optical microscope. The cover-slip comprises a planar portion of substantially rigid and transparent material and further comprises a tab contiguous with or adjacent to or attached with the planar portion. The tab is divertable from the plane of the planar portion along a predetermined bending region, thereby allowing holding and displacing the cover-slip e.g. when the cover-slip lies on a flat surface.
    Type: Application
    Filed: September 23, 2013
    Publication date: September 17, 2015
    Inventors: Alona Zilberberg, Amir Zilberberg
  • MIR-21 PROMOTER DRIVEN TARGETED CANCER THERAPY
    Publication number: 20150258216
    Abstract: The invention provides a nucleic acid construct comprising a promoter sequence derived from microRNA-21 (miR-21) linked to a nucleic acid sequence encoding an anti-cancer agent, an example of which is a toxin. The constructs of the invention are particularly useful for treating tumors expressing miR-21.
    Type: Application
    Filed: May 29, 2015
    Publication date: September 17, 2015
    Inventor: Alona Zilberberg
  • MIR-21 promoter driven targeted cancer therapy
    Patent number: 9044506
    Abstract: The invention provides a nucleic acid construct comprising a promoter sequence derived from microRNA-21 (miR-21) linked to a nucleic acid sequence encoding an anti-cancer agent, an example of which is a toxin. The constructs of the invention are particularly useful for treating tumors expressing miR-21.
    Type: Grant
    Filed: July 15, 2013
    Date of Patent: June 2, 2015
    Inventors: Rina Rosin-Arbesfeld, Ella Sklan, Alona Zilberberg, Naama David
  • MIR-21 PROMOTER DRIVEN TARGETED CANCER THERAPY
    Publication number: 20130310446
    Abstract: The invention provides a nucleic acid construct comprising a promoter sequence derived from microRNA-21 (miR-21) linked to a nucleic acid sequence encoding an anti-cancer agent, an example of which is a toxin. The constructs of the invention are particularly useful for treating tumors expressing miR-21.
    Type: Application
    Filed: July 15, 2013
    Publication date: November 21, 2013
    Applicant: Ramot at Tel Aviv University, Ltd.
    Inventors: Rina Rosin-Arbesfeld, Ella Sklan, Alona Zilberberg, Naama David
  • MIR-21 promoter driven targeted cancer therapy
    Patent number: 8492133
    Abstract: The invention provides a nucleic acid construct comprising a promoter sequence derived from microRNA-21 (miR-21) linked to a nucleic acid sequence encoding an anti-cancer agent, an example of which is a toxin. The constructs of the invention are particularly useful for treating tumors expressing miR-21.
    Type: Grant
    Filed: January 19, 2010
    Date of Patent: July 23, 2013
    Assignee: Ramot at Tel Aviv University, Ltd.
    Inventors: Rina Rosin-Arbesfeld, Ella Sklan, Alona Zilberberg, Naama David
  • MIR-21 PROMOTER DRIVEN TARGETED CANCER THERAPY
    Publication number: 20120065251
    Abstract: The invention provides a nucleic acid construct comprising a promoter sequence derived from microRNA-21 (miR-21) linked to a nucleic acid sequence encoding an anti-cancer agent, an example of which is a toxin. The constructs of the invention are particularly useful for treating tumors expressing miR-21.
    Type: Application
    Filed: January 19, 2010
    Publication date: March 15, 2012
    Inventors: Rina Rosin-Arbesfeld, Ella Sklan, Alona Zilberberg, Naama David